Safety and efficacy of Sofosbuvir in end stage kidney disease patient: Case report.

Authors

  • Salwa Mahmoud Elwasif, MD Mansoura University, Egypt.
  • Mohammed Taher Foaad, Center, Mansoura University, Egypt.
  • Mohammed Taher Foaad, Center, Mansoura University, Egypt.
  • Khaled Farouk Eldahshan, MD Mansoura University, Egypt.
  • Nabil Abdelfadil Elserwy Mansoura University, Egypt.
  • Mohamed Ahmed Elhadid Mansoura University, Egypt.
  • Mohamed Hamed Abbas Mansoura University, Egypt.
  • Ayman Fathi Refaie, MD Mansoura University, Egypt.
  • Ahmed Farouk Donia, MD Mansoura University, Egypt.
  • Ayman Maher Nagib, MD Mansoura University, Egypt.

DOI:

https://doi.org/10.53555/hsn.v2i6.269

Keywords:

Hepatitis C Virus, Sofosbuvir, Sofosbuvir, End stage kidney diseas

Abstract

Objectives: The existing standard of care for chronic hepatitis C virus (HCV) infection includes the use of pegylated interferon and ribavirin as primary
components of treatment, with the addition of a direct-acting antiviral therapy. Sofosbuvir, an oral nucleotide inhibitor of the HCV nonstructural protein 5B
RNA dependent RNA polymerase enzyme, was recently approved for use in combination with ribavirin and/or pegylated interferon for chronic HCV
infection, depending on the genotype. Sofosbuvir is orally administered, and peak plasma concentrations are not affected by food. The drug is renally
eliminated and does not require adjustment in mild to moderate renal insufficiency or in any degree of hepatic impairment. Case Report: A 62 yearold
lady, presented to our center in view of accidentally discovered high serum creatinine. Diagnosis of end stage renal disease was established by both
laboratory and radiological finding. Unfortunately she had hepatitis C virus infection during hemodialysis. She received Sofosbuvir with both early and
sustained viral response. Conclusion: We try to use Sofosbuvir in a well educated renal failure patient but we cannot grantee its effect on others.
Sofosbuvir is a promising drug, need more researches and randomized controlled trials among end stage renal disease patients.

Downloads

Download data is not yet available.

Author Biographies

Salwa Mahmoud Elwasif, MD, Mansoura University, Egypt.

Dept. of dialysis and transplantation, The Urology - Nephrology Center,

Mohammed Taher Foaad,, Center, Mansoura University, Egypt.

Dept. of dialysis and transplantation, The Urology - Nephrology Cente

Mohammed Taher Foaad,, Center, Mansoura University, Egypt.

Dept. of dialysis and transplantation, The Urology - Nephrology Cente

Khaled Farouk Eldahshan, MD, Mansoura University, Egypt.

Dept. of dialysis and transplantation, The Urology - Nephrology Center

Nabil Abdelfadil Elserwy, Mansoura University, Egypt.

Dept. of dialysis and transplantation, The Urology - Nephrology Center

Mohamed Ahmed Elhadid, Mansoura University, Egypt.

Dept. of dialysis and transplantation, The Urology - Nephrology Center

Mohamed Hamed Abbas, Mansoura University, Egypt.

Dept. of dialysis and transplantation, The Urology - Nephrology Center,

Ayman Fathi Refaie, MD, Mansoura University, Egypt.

Dept. of dialysis and transplantation, The Urology - Nephrology Center,

Ahmed Farouk Donia, MD, Mansoura University, Egypt.

Dept. of dialysis and transplantation, The Urology - Nephrology Center,

Ayman Maher Nagib, MD, Mansoura University, Egypt.

Dept. of dialysis and transplantation, The Urology - Nephrology Center,

Downloads

Published

2016-06-30

How to Cite

MD, S. M. E., Foaad, M. T., Foaad, M. T., MD, K. F. E., Elserwy, N. A., Elhadid, M. A., Abbas, M. H., MD, A. F. R., MD, A. F. D., & MD, A. M. N. (2016). Safety and efficacy of Sofosbuvir in end stage kidney disease patient: Case report. International Journal For Research In Health Sciences And Nursing, 2(6), 59–62. https://doi.org/10.53555/hsn.v2i6.269

Issue

Vol. 2 No. 6 (2016): International Journal For Research In Health Sciences And Nursing

Section

Articles